Janssen announced the availability of Invega Trinza (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia, following its approval in May 2015.

Invega Trinza, an atypical antipsychotic, is the first schizophrenia therapy to be administered as an injection four times a year. The mechanism of action of paliperidone is unknown but it has been proposed that the therapeutic activity of paliperidone in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

RELATED: New Schizophrenia Treatment Allows for Quarterly Dosing

Prior to treatment initiation, patients must be adequately treated with monthly Invega Sustenna (paliperidone palmitate) for injection for at least four months.

Invega Trinza is available as 273mg, 410mg, 546mg, and 819mg strengths in a kit containing a prefilled syringe and safety needles.

For more information call (800) 526-7736 or visit InvegaTrinza.com.